Vincerx Pharma, Inc. Common Stock (VINC) - Total Liabilities
Based on the latest financial reports, Vincerx Pharma, Inc. Common Stock (VINC) has total liabilities worth $2.62 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vincerx Pharma, Inc. Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Vincerx Pharma, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See VINC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Vincerx Pharma, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Vincerx Pharma, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fadel Partners Inc
LSE:FADL
|
UK | GBX6.56 Million |
|
Seed Innovations Ltd
LSE:SEED
|
UK | GBX153.00K |
|
CPPGroup Plc
LSE:CPP
|
UK | GBX22.06 Million |
|
ENVIROMETAL TECHN. O.N.
F:7N20
|
Germany | €1.51 Million |
|
URU Metals Ltd
LSE:URU
|
UK | GBX3.93 Million |
|
VELA TECHNOL.PLC LS-0001
F:IBNN
|
Germany | €6.00K |
|
ULTRA BRANDS LTD.
F:X6T
|
Germany | €1.40 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Vincerx Pharma, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Vincerx Pharma, Inc. Common Stock (VINC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vincerx Pharma, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vincerx Pharma, Inc. Common Stock (2019–2024)
The table below shows the annual total liabilities of Vincerx Pharma, Inc. Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.28 Million | -24.50% |
| 2023-12-31 | $7.00 Million | -39.79% |
| 2022-12-31 | $11.62 Million | -33.06% |
| 2021-12-31 | $17.36 Million | +215.26% |
| 2020-12-31 | $5.50 Million | +12411.36% |
| 2019-12-31 | $44.00K | -- |
About Vincerx Pharma, Inc. Common Stock
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops differentiated and novel therapies to address the unmet medical needs of patients with cancer in the United States. Its VersAptx bioconjugation platform combines different targeting, linker, and payload technologies to develop antibody-drug conjugates (ADC) and small molecule drug conjugates (SMDC); and prov… Read more